New multiple myeloma treatment approved in the U.S.
In June 2019, the U.S. FDA approved selinexor (Xpovio) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Myeloma patients had… Read More

In June 2019, the U.S. FDA approved selinexor (Xpovio) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Myeloma patients had… Read More
Two new research projects co-funded through a partnership between America’s The Leukemia & Lymphoma Society (LLS), Snowdome Foundation and Leukaemia Foundation will focus on acute… Read More
Professor Pimanda is incredibly curious. His observations around why cells behave in certain ways and respond variably to stimuli led him down a cell biology… Read More
Genetics is complex! At a very basic level we understand that when genes are altered or mutated the end result is a disease. This can… Read More
Professor Mark Dawson has been awarded the 2020 Frank Fenner Prize for Life Scientist of the Year. This prestigious award is one of the Australian… Read More
For the first time, the Snowdome Foundation pivoted its annual Blood Sweat and Tears of Joy educational event from face-to-face to virtual. This increased access… Read More
Since June 2020 the FDA has approved 6 new blood cancer treatments and expanded the use of an already available treatment. Sadly none are approved… Read More
Dr Michael Dickinson is the Lead of the Aggressive Lymphoma disease group within Clinical Haematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital. Michael… Read More
Four years ago, if you had a blood cancer in Western Australia (WA) and needed access to the latest treatment via a clinical trial, you… Read More
Chimeric Antigen Receptor (CAR) T cell therapy has been approved in Australia for forms of leukaemia and lymphoma for a while now, but we are… Read More